Lanean...
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
Brentuximab vedotin is a promising antibody–drug conjugate (ADC) targeting CD30 of tumor cells. It selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells and induces tumor cell apoptosis. Various clinical trials have provided evidence that it is effective in relapsed or refra...
Gorde:
| Argitaratua izan da: | Drug Des Devel Ther |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4376183/ https://ncbi.nlm.nih.gov/pubmed/25848209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S82007 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|